Skip to main content
Top
Published in: Journal of Gastroenterology 10/2011

01-10-2011 | Original Article—Liver, Pancreas, and Biliary Tract

Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma

Authors: Hideto Suzuki, Kazumoto Murata, Takaya Gotoh, Masao Kusano, Hiroshi Okano, Takashi Oyamada, Yoshikazu Yasuda, Masatoshi Imamura, Masatoshi Kudo, Masashi Mizokami, Atsushi Sakamoto

Published in: Journal of Gastroenterology | Issue 10/2011

Login to get access

Abstract

Background

Des-γ-carboxy prothrombin (DCP) is an established tumor marker for hepatocellular carcinoma (HCC), but the precise mechanism of its production remains unknown. We have recently demonstrated that cytoskeletal rearrangement during the phenotypic changes involved in epithelial mesenchymal transition (EMT) plays a crucial role in DCP production through the impairment of vitamin K uptake. However, DCP production in long-lasting severe hypoxic conditions with nutrient deprivation–such as transarterial embolization–remains unknown.

Methods

We examined the effects of long-lasting hypoxia with nutrient deprivation, as well as the constitutive expression of hypoxia-inducible factor (HIF)-1α, on EMT status, DCP production, and protein synthesis in human hepatoma cell lines by enzyme-linked immunosorbent assay, immunofluorescent studies, and western blotting. Immunohistochemistry findings for DCP, anti-hepatocyte paraffin 1 (Hep Par 1), and vimentin were examined using human resected HCC samples.

Results

Both severe hypoxia with nutrient deprivation and HIF-1α transfection led to the cessation of DCP production, by attenuating protein synthesis through the hypophosphorylation of mammalian target of rapamycin and its effector proteins, indicative of a further phenotypic shift involving impaired liver-specific protein synthesis. In immunohistochemistry, the distribution of DCP- and Hep Par 1-positive HCC cells was mostly similar and vimentin-positive HCC cells were frequently observed in the areas that were negative for Hep Par 1 and/or DCP.

Conclusions

HCC cells produce DCP when they undergo mild phenotypic changes. However, when HCC cells adopt mesenchymal properties they lose their capacity for protein synthesis, and the production of DCP is attenuated. Building upon our previous works, it appears that DCP could be a unique tumor marker that reflects the stepwise phenotypic changes of HCC.
Literature
1.
go back to reference Liebman H, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427–31.PubMedCrossRef Liebman H, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427–31.PubMedCrossRef
2.
go back to reference Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma-carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.PubMedCrossRef Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma-carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.PubMedCrossRef
3.
go back to reference Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-γ-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1541–8.PubMedCrossRef Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-γ-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1541–8.PubMedCrossRef
4.
go back to reference Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma. Hepatol Res. 2008;38:37–51.PubMedCrossRef Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma. Hepatol Res. 2008;38:37–51.PubMedCrossRef
5.
go back to reference Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systemic review. Hepatol Int. 2008;2:17–30.PubMedCrossRef Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systemic review. Hepatol Int. 2008;2:17–30.PubMedCrossRef
6.
go back to reference Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, et al. The utility of AFP-L3% in the diagnosis of hepatocellular carcinoma: evaluation in a U.S. referral population. Clin Gastroenterol Hepatol. 2007;5:394–402.PubMedCrossRef Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, et al. The utility of AFP-L3% in the diagnosis of hepatocellular carcinoma: evaluation in a U.S. referral population. Clin Gastroenterol Hepatol. 2007;5:394–402.PubMedCrossRef
7.
go back to reference Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.PubMedCrossRef Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.PubMedCrossRef
8.
go back to reference Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, HALT-C Trial Group, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502.PubMedCrossRef Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, HALT-C Trial Group, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502.PubMedCrossRef
9.
go back to reference Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30:3–16.PubMedCrossRef Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30:3–16.PubMedCrossRef
10.
go back to reference Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007;26:319–31.PubMedCrossRef Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007;26:319–31.PubMedCrossRef
11.
go back to reference Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119:1417–9.PubMedCrossRef Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119:1417–9.PubMedCrossRef
13.
go back to reference Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510–4.PubMedCrossRef Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510–4.PubMedCrossRef
14.
go back to reference Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat Cell Biol. 2008;10:295–305.PubMedCrossRef Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat Cell Biol. 2008;10:295–305.PubMedCrossRef
15.
go back to reference Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003;63:1138–43.PubMed Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003;63:1138–43.PubMed
16.
go back to reference Luo Y, He DL, Ning L, Shen SL, Li L, Li X, et al. Over-expression of hypoxia-inducible factor-1α increases the invasive potency of LNCap cells in vitro. BJU Int. 2006;98:1315–9.PubMedCrossRef Luo Y, He DL, Ning L, Shen SL, Li L, Li X, et al. Over-expression of hypoxia-inducible factor-1α increases the invasive potency of LNCap cells in vitro. BJU Int. 2006;98:1315–9.PubMedCrossRef
17.
go back to reference Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Over expression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59:5830–5.PubMed Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Over expression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59:5830–5.PubMed
18.
go back to reference Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119:1438–49.PubMedCrossRef Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119:1438–49.PubMedCrossRef
19.
go back to reference Murata K, Sakamoto A. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2008;33:1149–55.PubMed Murata K, Sakamoto A. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2008;33:1149–55.PubMed
20.
go back to reference Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2009;35:1005–14.PubMedCrossRef Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2009;35:1005–14.PubMedCrossRef
21.
go back to reference Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Hypoxia-induced des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36:161–70.PubMed Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Hypoxia-induced des-γ-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36:161–70.PubMed
22.
go back to reference Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment. Cancer. 2006;106:867–72.PubMedCrossRef Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment. Cancer. 2006;106:867–72.PubMedCrossRef
23.
go back to reference Shimada M, Yonemura Y, Ijichi H, Harada N, Shiotani S, Ninomiya M, et al. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc. 2005;37:1177–9.PubMedCrossRef Shimada M, Yonemura Y, Ijichi H, Harada N, Shiotani S, Ninomiya M, et al. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc. 2005;37:1177–9.PubMedCrossRef
24.
go back to reference Arsham AM, Howell JJ, Simons MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem. 2003;278:29655–60.PubMedCrossRef Arsham AM, Howell JJ, Simons MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem. 2003;278:29655–60.PubMedCrossRef
25.
go back to reference Pouyssegur J, Dayan F, Mazure NM. Hypoxia signaling in cancer and approaches to enforce tumor regression. Nature. 2006;441:437–43.PubMedCrossRef Pouyssegur J, Dayan F, Mazure NM. Hypoxia signaling in cancer and approaches to enforce tumor regression. Nature. 2006;441:437–43.PubMedCrossRef
26.
go back to reference Wouters BG, Koritzinsky M. Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851–64.PubMedCrossRef Wouters BG, Koritzinsky M. Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851–64.PubMedCrossRef
27.
go back to reference Boutilier RG, St-Pierre J. Surviving hypoxia without really dying. Comp Biochem Physiol A Mol Integr Physiol. 2000;126:481–90.PubMedCrossRef Boutilier RG, St-Pierre J. Surviving hypoxia without really dying. Comp Biochem Physiol A Mol Integr Physiol. 2000;126:481–90.PubMedCrossRef
28.
29.
go back to reference Gulhati P, Bowen KA, Liu J, et al. mTORC1 and mTORC2 regulate EMT, motility and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011;71:3246–56. Gulhati P, Bowen KA, Liu J, et al. mTORC1 and mTORC2 regulate EMT, motility and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011;71:3246–56.
30.
go back to reference Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest. 2008;88:78–88.PubMedCrossRef Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest. 2008;88:78–88.PubMedCrossRef
31.
go back to reference Kumagai I, Masuda T, Sato S, Ishikawa K. Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histological grade and histological pattern. Hepatol Res. 2001;20:312–9.PubMedCrossRef Kumagai I, Masuda T, Sato S, Ishikawa K. Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histological grade and histological pattern. Hepatol Res. 2001;20:312–9.PubMedCrossRef
32.
go back to reference Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544–50.PubMedCrossRef Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544–50.PubMedCrossRef
33.
go back to reference Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology. 2008;75:91–8.PubMedCrossRef Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology. 2008;75:91–8.PubMedCrossRef
34.
go back to reference Ueshima K, Kudo M. PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinoma. Kanzo. 2010;51:681–3. (in Japanese).CrossRef Ueshima K, Kudo M. PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinoma. Kanzo. 2010;51:681–3. (in Japanese).CrossRef
Metadata
Title
Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma
Authors
Hideto Suzuki
Kazumoto Murata
Takaya Gotoh
Masao Kusano
Hiroshi Okano
Takashi Oyamada
Yoshikazu Yasuda
Masatoshi Imamura
Masatoshi Kudo
Masashi Mizokami
Atsushi Sakamoto
Publication date
01-10-2011
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 10/2011
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-011-0432-8

Other articles of this Issue 10/2011

Journal of Gastroenterology 10/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.